Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 117-131 , February 2009

Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents

  • Simona Pisanti, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
    • ,
  • Anna Maria Malfitano, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
    • ,
  • Claudia Grimaldi, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
    • ,
  • Antonietta Santoro, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
    • ,
  • Patrizia Gazzerro, PhD (Doctor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
    • ,
  • Chiara Laezza, PhD (Doctor)

      Affiliations

    • Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy
    • ,
  • Maurizio Bifulco, MD (Professor)

      Affiliations

    • Department of Pharmaceutical Sciences, University of Salerno, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 089 969742; Fax: +39 089 969602.

References 

  1. Peters H, Nahas GG. A brief history of four millennia (B.C. 2000-A.D. 1974). In:  Nahas GG,  Sutin KM,  Harvey D, et al. editor. Marihuana and medicine. Totowa, NJ: Humana Press; 1999;p. 3–7
  2. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society. 1964;86:1646–1647
  3. Howlett AC, Barth F, Bonner TI, et al. Classification of cannabinoid receptors. Pharmacological Reviews. 2002;54:161–202
  4. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology. 2004;141:765–774
  5. Di Marzo V. Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochimica et Biophysica Acta. 1998;1392:153–175
  6. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006;58:389–462
  7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65
  8. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology. 1986;29:307–313
  9. Bouaboula M, Poinot-Chazel C, Bourrie B, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. The Biochemical Journal. 1995;312:637–641
  10. Gomez Del Pulgar T, De Ceballos ML, Guzman M, et al. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. The Journal of Biological Chemistry. 2002;277:36527–36533
  11. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences of the United States of America. 1992;89:3825–3829
  12. Bifulco M, Di Marzo V. The endocannabinoid system as a target for the development of new drugs for cancer therapy. Nature Medicine. 2002;8:547–550
  13. Bifulco M, Laezza C, Pisanti S, et al. Cannabinoids and cancer: pros and cons of an antitumour strategy. British Journal of Pharmacology. 2006;148:123–135
  14. Bifulco M, Malfitano AM, Pisanti S, et al. Endocannabinoids in endocrine and related tumours. Endocrine-related Cancer. 2008;15:391–408
  15. De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:8375–8380
  16. Melck D, Rueda D, Galve-Ropher I, et al. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters. 1999;463:235–240
  17. Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptor and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000;141:118–126
  18. Laezza C, Pisanti S, Crescenzi E, et al. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Letters. 2006;13(580):6076–6082
  19. Grimaldi C, Pisanti S, Laezza C, et al. Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research. 2006;15(312):363–373
  20. McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. Journal of Immunology. 2005;15(174):3281–3289
  21. Caffarel MM, Sarrio D, Palacios J, et al. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Research. 2006;66:6615–6621
  22. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. The Journal of Pharmacology and Experimental Therapeutics. 2006;318:1375–1387
  23. Sarnataro D, Pisanti S, Santoro A, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid rafts mediated mechanism. Molecular Pharmacology. 2006;70:1298–1306
  24. Mimeault M, Pommery N, Wattez N, et al. Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 2003;56:1–12
  25. Ruiz L, Miguel A, Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Letters. 1999;458:400–404
  26. Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Research. 2005;65:1635–1641
  27. Sanchez MG, Sanchez AM, Ruiz-Llorente L, et al. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Letters. 2003;555:561–566
  28. Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine. 2000;6:313–319
  29. Sanchez C, de Ceballos ML, del Pulgar TG, et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Research. 2001;61:5784–5789
  30. Ellert-Miklaszewska A, Kaminska B, Konarska L. Cannabinoids downregulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cellular Signalling. 2005;17:25–37
  31. McAllister SD, Chan C, Taft RJ, et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. Journal of Neuro-oncology. 2005;74:31–40
  32. Hinz B, Ramer R, Eichele K, et al. R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochemical and Biophysical Research Communications. 2004;324:621–626
  33. Bifulco M, Laezza C, Portella G, et al. Control by the endogenous cannabinoid system of ras oncogene dependent tumor growth. The FASEB Journal. 2001;15:2745–2747
  34. Portella G, Laezza C, Laccetti P, et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. The FASEB Journal. 2003;17:1771–1773
  35. Bifulco M, Laezza C, Valenti M, et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. The FASEB Journal. 2004;18:1606–1608
  36. Maccarrone M, Lorenzon T, Bari M, et al. Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. The Journal of Biological Chemistry. 2000;275:31938–31945
  37. McKallip RJ, Lombard C, Fisher M, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002;100:627–634
  38. Flygare J, Gustafsson K, Kimby E, et al. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Letters. 2005;579:6885–6889
  39. Gustafsson K, Christensson B, Sander B, et al. Cannabinoid receptormediated apoptosis induced by R(+)-methanandamide and Win55, 212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Molecular Pharmacology. 2006;70:1612–1620
  40. Herrera B, Carracedo A, Diez-Zaera M, et al. p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Letters. 2005;579:5084–5088
  41. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125:677–687
  42. Patsos HA, Hicks DJ, Dobson RR, et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut. 2005;54:1741–1750
  43. Izzo AA, Aviello G, Petrosino S, et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. Journal of Molecular Medicine. 2008;86:89–98
  44. Wang D, Wang H, Ning W, et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Research. 2008;68:6468–6476
  45. Casanova ML, Blazquez C, Martinez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. The Journal of Clinical Investigation. 2003;111:43–50
  46. Munson AE, Harris LS, Friedman MA, et al. Antineoplastic activity of cannabinoids. Journal of the National Cancer Institute. 1975;55:597–602
  47. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Research. 2004;64:1943–1950
  48. Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Research. 2006;66:6748–6755
  49. Blazquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. The FASEB Journal. 2003;17:529–531
  50. Pisanti S, Borselli C, Oliviero O, et al. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. Journal of Cellular Physiology. 2007;211:495–503
  51. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. Journal of the National Cancer Institute. 2008;100:59–69
  52. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. Journal of Leukocyte Biology. 2003;74:486–496
  53. Malfitano AM, Matarese G, Pisanti S, et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. Journal of Neuroimmunology. 2006;171:110–119
  54. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Annals of Surgical Oncology. 2004;11:328
  55. Newton CA, Klein TW, Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by ▵-9-tetrahydrocannabinol injection. Infection and Immunity. 1994;62:4015
  56. Vieweg J, Su Z, Dahm P, et al. Reversal of tumor-mediated immunosuppression. Clinical Cancer Research. 2007;13:727s–732s
  57. Zhu Li X, Sharma S, Stolida M, et al. ▵-9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. The Journal of Immunology. 2000;165:373–380
  58. Yuan M, Kiertscher SM, Cheng Q, et al. ▵9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. Journal of Neuroimmunology. 2002;133:124–131
  59. Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genetics and Cytogenetics. 2006;171:31–38
  60. Islam TC, Asplund AC, Lindvall JM, et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia. 2003;17:1880–1890
  61. Calatozzolo C, Salmaggi A, Pollo B, et al. Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurological Sciences. 2007;28:304–310
  62. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001;357:539–545
  63. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology. 2004;14:433–439
  64. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  65. Yang CR, Hsieh SL, Ho FM, et al. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-nB-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. Journal of Immunology. 2005;174:1647–1656
  66. Molina-Holgado F, Molina-Holgado E, Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Letters. 1998;433(1–2):139–242
  67. Mazzari S, Canella R, Petrelli L, et al. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. European Journal of Pharmacology. 1996;300(3):227–236
  68. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. European Journal of Pharmacology. 1998;345(2):145–153
  69. Michalski CW, Laukert T, Sauliunaite D, et al. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology. 2007;132(5):1968–1978
  70. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. The Journal of Clinical Investigation. 2004;113(8):1202–1209
  71. Joseph J, Niggemann B, Zaenker KS, et al. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology, Immunotherapy. 2004;53(8):723–728
  72. Zheng D, Bode AM, Zhao Q, et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Research. 2008;68(10):3992–3998
  73. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of D9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer. 2006;95:197–203
  74. Bifulco M, Grimaldi C, Gazzerro P, et al. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Molecular Pharmacology. 2007;71:1445–1456
  75. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. The Journal of Biological Chemistry. 1997;272:22330–22339
  76. Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Molecular Pharmacology. 2006;69:471–478
  77. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine. 2006;12:671–676
  78. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care in Cancer. 2003;11:137–143
  79. Andrews PL, Naylor RJ, Joss RA. Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies. Support Care in Cancer. 1998;6:197–203
  80. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sciences. 2004;74:1317–1324
  81. Carlo Di, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opinion on Investigational Drugs. 2003;12:39–49
  82. Maida V, Ennis M, Irani S, et al. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. The Journal of Supportive Oncology. 2008;6:119–124
  83. Walsh D, Kirkova J, Davis MP. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. Journal of Pain and Symptom Management. 2005;30:493–495
  84. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion. 2007;23:533–543
  85. Maida V. The synthetic cannabinoid Nabilone improves pain and symptom management in cancer patients. SABCS, 2006, abstract 3145.
  86. Zutt M, Hänssle H, Emmert S, et al. Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases. Der Hautarzt. 2006;57:423–427
  87. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology. 2006;24:3394–3400
  88. Sutton IR, Daeninck P. Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. The Journal of Supportive Oncology. 2006;4:531–535
  89. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology. 2002;20:567–573
  90. Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences. 1995;56:2097–2102
  91. Nelson K, Walsh D, Deeter P, et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Journal of Palliative Care. 1994;10:14–18
  92. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom Management. 1991;6:352–359
  93. Cherny NI. The pharmacologic management of cancer pain. Oncology. 2004;18:1499–1515
  94. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacology & Therapeutics. 2002;95:127–135
  95. Potenzieri C, Harding-Rose C, Simone DA. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Research. 2008;1215:69–75
  96. Pertwee RG. Cannabinoid receptors and pain. Progress in Neurobiology. 2001;63:569–611
  97. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Frontiers of Hormone Research. 2008;36:135–145
  98. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2002;410:822–825
  99. Wilson MM, Philpot C, Morley JE. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?–a pilot study. The Journal of Nutrition, Health & Aging. 2007;11:195–198

PII: S1521-690X(09)00005-0

doi: 10.1016/j.beem.2009.02.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 117-131 , February 2009

Article Tools